Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 216

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 216
---
, assuming the shares were outstanding since January 1, 2023. As the Business Combination and other related events are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares issuable in connection with the Business Combination have been outstanding for the entire period presented. No unexercised stock options and warrants, which are discussed elsewhere in this proxy statement/prospectus, were included in the earnings per share calculation as they would be anti-dilutive.

| ​                                                                            | ​ | ​ | Nine Months Ended September 30, 2024 |   |            |   |   |   |                            |   |            |   | ​ | ​ | Year Ended December 31, 2023     |   |            |   |   |   |                            |   |            |   | ​ |
|:-----------------------------------------------------------------------------|:--|:--|:-------------------------------------|:--|-----------:|:--|:--|:--|:---------------------------|:--|-----------:|:--|:--|:--|:---------------------------------|:--|-----------:|:--|:--|:--|:---------------------------|:--|-----------:|:--|:--|
| ​                                                                            | ​ | ​ | Assuming NoAdditionalRedemptions     |   |            |   | ​ | ​ | AssumingMaximumRedemptions |   |            |   | ​ | ​ | Assuming NoAdditionalRedemptions |   |            |   | ​ | ​ | AssumingMaximumRedemptions |   |            |   | ​ |
| Pro forma net loss                                                           | ​ | ​ | ​                                    | $ |     -5,541 | ​ | ​ | ​ | ​                          | $ |     -5,541 | ​ | ​ | ​ | ​                                | $ |    -10,500 | ​ | ​ | ​ | ​                          | $ |    -10,500 | ​ | ​ |
| Pro forma weighted average shares outstanding, basic and diluted             | ​ | ​ | ​                                    | ​ | 26,774,477 | ​ | ​ | ​ | ​                          | ​ | 26,600,000 | ​ | ​ | ​ | ​                                | ​ | 26,774,477 | ​ | ​ | ​ | ​                          | ​ | 26,774,477 | ​ | ​ |
| Pro forma net loss